Euclidean Capital LLC

NEW YORK, NY · Quarter end: Sep 30, 2026 · Filed with SEC: Nov 16, 2026 · Open the SEC source ↗
Portfolio Return (1Y)——
Portfolio Value (AUM)Total value of the fund's US stock portfolio reported to the SEC.$323.6M2026 Q3
Positions10
Top-10 ConcentrationPercent of the portfolio in the 10 largest holdings. High means the fund is concentrated in few stocks.100.0%

Euclidean Capital LLC reported 10 positions worth $323.6M as of September 30, 2026 (13F filed November 16, 2026). Largest holding: VEU (83.2%). Biggest move: exit VTV ($113.3M).

10 positions shown
#SymbolCompanyValue ↓% Port.Shares1YYTDSince reported
▸ 1 VEUVanguard Intl Equity$269.1M83.15%3,243,484———
▸ 2 INDAIshares Tr$17.3M5.33%369,600———
▸ 3 ORICOric Pharmaceuticals$13.3M4.12%989,410——-44.2%
▸ 4 TMSTeamshares$8.0M2.47%1,099,974——-28.0%
▸ 5 FHTXFoghorn Therapeutics$5.6M1.74%1,573,761———
▸ 6 PMVPPMV Pharmaceuticals$4.4M1.36%2,627,643———
▸ 7 SRZNSurrozen$2.8M0.87%87,696——-1.8%
▸ 8 ALECAlector$2.4M0.75%1,307,858——+37.3%
▸ 9 TNYATenaya Therapeutics$613.1K0.19%1,015,705——-42.2%
▸ 10 MRLNMerlin$89.5K0.03%47,610——-49.5%

Read the 2026-Q2 quarterly report · 13F Filing Calendar

🔔 Tell me when this fund files a new 13F

No account needed: in your inbox the morning it is published.

Frequently Asked Questions

What stocks does Euclidean Capital LLC hold as of Q3 2026?

Euclidean Capital LLC reported 10 positions worth $323.6M in its Q3 2026 13F filing. Largest positions: VEU (83.2%), INDA (5.3%), ORIC (4.1%), TMS (2.5%) and FHTX (1.7%).

What did Euclidean Capital LLC buy in Q3 2026?

New positions: MRLN.

What did Euclidean Capital LLC sell in Q3 2026?

Sold out entirely: VTV and SURROZEN INC.

13F data shows quarter-end positions, is delayed by up to 45 days and covers only long positions in US-listed securities; short positions, most derivatives and non-US assets are not reported.